Cheryl V. Rahman
Adjuvant chemotherapy for brain tumors delivered via a novel intra-cavity moldable polymer matrix
Rahman, Cheryl V.; Smith, Stuart J.; Morgan, Paul S.; Langmack, Keith A.; Clarke, Phil A.; Ritchie, Alison A.; Macarthur, Donald C.; Rose, Felicity R.A.J.; Shakesheff, Kevin M.; Grundy, Richard G.; Rahman, Ruman
Stuart J. Smith
Paul S. Morgan
Keith A. Langmack
Phil A. Clarke
Alison A. Ritchie
Donald C. Macarthur
FELICITY ROSE firstname.lastname@example.org
Professor of Biomaterials and Tissue Engineering
Kevin M. Shakesheff
Richard G. Grundy
RUMAN RAHMAN RUMAN.RAHMAN@NOTTINGHAM.AC.UK
Polymer-based delivery systems offer innovative intra-cavity administration of drugs, with the potential to better target micro-deposits of cancer cells in brain parenchyma beyond the resected cavity. Here we evaluate clinical utility, toxicity and sustained drug release capability of a novel formulation of poly(lactic-co-glycolic acid) (PLGA)/poly(ethylene glycol) (PEG) microparticles.
PLGA/PEG microparticle-based matrices were molded around an ex vivo brain pseudo-resection cavity and analyzed using magnetic resonance imaging and computerized tomography. In vitro toxicity of the polymer was assessed using tumor and endothelial cells and drug release from trichostatin A-, etoposide- and methotrexate-loaded matrices was determined. To verify activity of released agents, tumor cells were seeded onto drug-loaded matrices and viability assessed.
PLGA/PEG matrices can be molded around a pseudo-resection cavity wall with no polymer-related artifact on clinical scans. The polymer withstands fractionated radiotherapy, with no disruption of microparticle structure. No toxicity was evident when tumor or endothelial cells were grown on control matrices in vitro. Trichostatin A, etoposide and methotrexate were released from the matrices over a 3-4 week period in vitro and etoposide released over 3 days in vivo, with released agents retaining cytotoxic capabilities. PLGA/PEG microparticle-based matrices molded around a resection cavity wall are distinguishable in clinical scanning modalities. Matrices are non-toxic in vitro suggesting good biocompatibility in vivo. Active trichostatin A, etoposide and methotrexate can be incorporated and released gradually from matrices, with radiotherapy unlikely to interfere with release.
The PLGA/PEG delivery system offers an innovative intra-cavity approach to administer chemotherapeutics for improved local control of malignant brain tumors.
Rahman, C. V., Smith, S. J., Morgan, P. S., Langmack, K. A., Clarke, P. A., Ritchie, A. A., …Rahman, R. (2013). Adjuvant chemotherapy for brain tumors delivered via a novel intra-cavity moldable polymer matrix. PLoS ONE, 8(10), Article e77435. https://doi.org/10.1371/journal.pone.0077435
|Journal Article Type||Article|
|Acceptance Date||Sep 2, 2013|
|Publication Date||Oct 14, 2013|
|Deposit Date||Oct 18, 2016|
|Publicly Available Date||Oct 18, 2016|
|Publisher||Public Library of Science|
|Peer Reviewed||Peer Reviewed|
PLoS ONE 2013 Rahman.pdf
Copyright information regarding this work can be found at the following address: http://creativecommons.org/licenses/by/4.0
You might also like
Aberrant visual pathway development in albinism: from retina to cortex
The MRI central vein marker: differentiating PPMS from RRMS and ischaemic SVD